Capstan Therapeutics to Present Preclinical Data at SITC Demonstrating Rapid Anti-Primary B Cell and Anti-Tumor Activity in Mice with Proprietary Targeted Lipid Nanoparticles Delivering an Anti-CD19 CAR mRNA Construct

SAN DIEGO–(BUSINESS WIRE)–Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery utilizing targeted lipid nanoparticles (tLNP), today announced it will present preclinical data showing rapid and robust anti-tumor and anti-primary B cell activity in humanized mice by tLNP administration delivering an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR), at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, California.

“These data highlight the potential for Capstan’s targeted LNP-mRNA platform to provide a truly disruptive, off-the-shelf, cell-free, scalable and tunable solution for patients without the need for harsh lymphodepletion conditioning or viral vectors that are required for conventional ex vivo cell therapies,” said Adrian Bot, M.D., Ph.D., Capstan’s Chief Scientific Officer, and Executive Vice President of R&D. “We have demonstrated efficient and therapeutically relevant delivery of mRNA CAR payloads to human T cells. This resulted in rapid and profound pharmacodynamic effect in two mouse models, comprising eradication of human primary B cells or Nalm6 leukemic cells, respectively. These data provide a springboard for developing novel, in vivo CAR therapies that may overcome access and clinical performance issues with currently available ex vivo CAR therapies, with broad applicability in autoimmune and oncology indications.”

Poster Details:

Title: In vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology

Presentation type: Poster

Session: Poster Hall

Date and time: Saturday, November 4, 2023: 9:00 AM – 8:30 PM

Lead authors: Gregor Adams, Ph.D., and Haig Aghajanian, Ph.D.

A copy of the poster will be added to the “Publications and News” section of Capstan’s website at www.capstantx.com/.

About Capstan Therapeutics (www.capstantx.com)

Capstan Therapeutics, Inc. is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.

Contacts

Investors:
Miguel Arcinas

Vice President of Corporate Development

Capstan Therapeutics, Inc.

[email protected]

Media:
Rhiannon Jeselonis

Ten Bridge Communications

[email protected]